lenalidomide,rituximab,acalabrutinib
astrazeneca
['mantle,(-dismantle)', 'lenalidomide', 'elevate,(-elevate uc),(-elevateuc),(-elevate-uc),(-elevate rr),(-elevaterr),(-elevate-rr),(-elevate tn),(-elevatetn),(-elevate-tn)', 'ritux', 'acalabrutinib', ' lena', 'lymsm', 'imab ']
first up in the #ash22 mantle cell session: phase 2 single-arm study of acala, len, and rituximab in frontline mcl with mrd-driven de-escalation. only 24 pts, most at least intermediate mipi risk. #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????